Tamoxifen: A Tracking Guide for the SERM

Tamoxifen is a selective estrogen receptor modulator (SERM): it blocks estrogen receptors in some tissues (notably breast) while acting estrogen-like in others (bone, liver). It is a long-established breast-cancer treatment and prevention drug. In performance contexts it is used off-label to treat or prevent gynecomastia and to help restart the HPTA after steroid use.

This is an educational tracking guide. Tamoxifen is prescription-only and carries boxed warnings. It deserves respect, not casual use.

What it does

• Blocks estrogen at the breast - the basis for treating and preventing gynecomastia
• At the hypothalamus and pituitary, it raises LH and FSH, which can raise testosterone - the basis for HPTA-restart use
• Acts estrogen-like in bone and on lipids, which is partly protective
• Has pro-thrombotic and endometrial effects that drive its serious warnings

What people use it for (off-label)

• Treating gynecomastia symptoms (early nipple swelling and tenderness)
• Post-cycle HPTA recovery, often paired with or instead of clomiphene
• Note: it does not lower estrogen the way an aromatase inhibitor does; it blocks estrogen's action in select tissues

What to track daily

• Dose, timing
• Gynecomastia symptoms (nipple tenderness, lumps) and any change
• Mood and libido
• Any leg swelling, pain, redness, or warmth - possible clot signs, report urgently
• Visual changes (rare but documented)

What to track weekly

• Subjective well-being and libido
• Symptom resolution if treating gynecomastia
• Any side effects accumulating

Bloodwork worth doing

• Baseline and follow-up for HPTA-restart use: LH, FSH, total and free testosterone, sensitive estradiol
• Lipids, since SERMs affect them
• The point of restart use is to see LH, FSH, and testosterone climb back

Realistic expectations

• For early gynecomastia, it can halt or reverse symptoms; established glandular tissue may not resolve
• For HPTA restart, recovery is gradual and not guaranteed, depending on what suppressed you and for how long
• It manages estrogen's effects in tissues; it does not crush serum estrogen

Common mistakes

• Using it as if it were an aromatase inhibitor (it is not)
• Ignoring clot-risk symptoms
• Treating established, long-standing gynecomastia and expecting it to vanish
• Running PCT protocols without baseline or follow-up bloods

A tracking template

• Pre: baseline LH, FSH, testosterone, estradiol if doing a restart
• On: daily symptom and side-effect logs, watch for clot signs
• Follow-up: recheck hormone panel to confirm recovery

Safety notes

Boxed warnings include uterine malignancies and serious thromboembolic events (blood clots). Report leg swelling or pain, chest pain, or breathlessness immediately. Prescription-only and not a casual ancillary; use under a physician who can weigh the clot and other risks.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.